Thymosin Alpha-1 and Metformin Interaction: What Patients and Clinicians Need to Know

Does thymosin alpha-1 interact with metformin?

What can be said comes from each drug's own data: metformin's labeled interaction list and the peptide's pharmacokinetics.

Metformin hydrochloride tablets are a biguanide used as an adjunct to diet and exercise for type 2 diabetes in adults and children 10 years and older; that label covers the immediate-release tablets [1].

The label's drug interactions section names five groups: carbonic anhydrase inhibitors such as topiramate, zonisamide, acetazolamide and dichlorphenamide; drugs that reduce metformin clearance through OCT2 and MATE transporters, with ranolazine, vandetanib, dolutegravir and cimetidine as examples; alcohol; insulin and insulin secretagogues; and drugs that can raise blood glucose [1]. Thymosin alpha-1 appears in none of those groups [1]. For the first two groups the label says use may increase lactic acidosis risk, and it advises more frequent monitoring (carbonic anhydrase inhibitors) or weighing benefits and risks (clearance reducers) [1].

Do the two drugs overlap in what they do?

Not according to their own descriptions. Metformin lowers basal and post-meal glucose, reduces hepatic glucose production, reduces intestinal glucose absorption and improves insulin sensitivity, while insulin secretion stays unchanged [1]. Thymosin alpha-1 is described as an immune modulator that augments T-cell function [2]. These descriptions do not identify a direct interaction between the two [1][2].

What the metformin label warns about

The boxed warning covers metformin-associated lactic acidosis. Postmarketing cases have resulted in death, hypothermia, hypotension and resistant bradyarrhythmias, and onset is often subtle: malaise, myalgias, respiratory distress, somnolence and abdominal pain [1]. The laboratory picture is blood lactate above 5 mmol/L, anion gap acidosis, a raised lactate to pyruvate ratio, and metformin plasma levels generally above 5 mcg/mL [1]. Risk factors the label names include renal impairment, concomitant use of certain drugs, age 65 or older, radiologic studies with contrast, surgery and other procedures, hypoxic states such as acute congestive heart failure, excessive alcohol intake, hepatic impairment and mitochondrial disease [1]. If lactic acidosis is suspected, the label says to stop metformin and give supportive care in hospital, with prompt hemodialysis recommended [1].

The label also gives detailed kidney rules. It says the postmarketing lactic acidosis cases primarily occurred in patients with significant renal impairment, and that an eGFR should be obtained before starting and at least yearly in all patients, more often in people at risk of renal impairment such as the elderly [1]. Metformin is contraindicated below an eGFR of 30 mL/min/1.73 m2, starting is not recommended at 30 to 45, and if eGFR later falls below 45 the benefit and risk of continuing should be reassessed [1]. The label also says to stop metformin around iodinated contrast procedures in patients with an eGFR of 30 to 60, a history of liver disease, alcoholism or heart failure, or when intra-arterial contrast is used, then recheck eGFR 48 hours later [1].

Two other label items are worth knowing. Subnormal vitamin B12 levels were seen in about 7% of patients in 29-week trials, and the label says to measure hematologic parameters annually and vitamin B12 every 2 to 3 years [1]. Alcohol potentiates metformin's effect on lactate metabolism, and the label warns against excessive intake [1].

What is known about thymosin alpha-1 in the body

Thymosin alpha-1 is a 28-amino-acid peptide with an acetylated N-terminal end, and thymalfasin is the synthetic version with the same sequence [3]. After subcutaneous injection in healthy volunteers it is absorbed quickly, peaking at about 0.7 to 2 hours, with a short half-life of about 1.8 to 2.6 hours and no accumulation after five daily doses [2][3].

Safety reporting is sparse. FDA's search of its adverse-event database on April 22, 2024 found zero reports for thymosin alpha-1 [3]. In a 2026 Cochrane review of hepatitis B trials, thymosin alpha-1 may have caused fewer serious adverse events than comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1,056 people; low-certainty evidence) and fewer non-serious events (risk ratio 0.47, 95% CI 0.27 to 0.83; very low-certainty evidence) [4].

The Italian Zadaxin label says it is not for children and is contraindicated in pregnancy and breastfeeding. It advises caution in people with allergies or autoimmune disease, and caution with other immune-modulating drugs [3].

Is thymosin alpha-1 approved in the United States?

No. Thymosin alpha-1 is not FDA-approved, and FDA's December 2024 review found no US application for it [3]. It has four US orphan drug designations, which are a separate process from approval [3]. Outside the US, FDA lists Zadaxin as authorized in Italy as an adjuvant to influenza vaccination in immunocompromised people, in India for chronic hepatitis B in adults with compensated liver disease and virus replication, and in Hong Kong [3]. Two older reviews written by authors tied to the product's developer describe approvals in more than 30 or more than 35 countries [5][6].

Frequently asked questions